Literature DB >> 527639

Ergotism in a patient with a portosystemic shunt.

V Hansteen, C Eika, S Birkeland.   

Abstract

A case of ergotism is described in a patient with Banti's syndrome in whom a porto-systemic shunt had been made three times. She was admitted to hospital with severe ischaemia of the extremities after having taken a single oral dose of 1 mg ergotamine tartrate. Her condition improved rapidly after 2 to 3 days and the circulation was normal after one week. The possible mechanism of ergotism in this patient is discussed. Although the plasma concentration of ergotamine was not measured, the likeliest explanation was that the serious side effects were related to the altered pharmacokinetics and loss of first-pass metabolism of the drug due to the venous bypass of the liver.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 527639     DOI: 10.1007/BF00568205

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Severe arteriospasm after use of ergotamine tartrate suppositories. Report of a case.

Authors:  J R YOUNG; A W HUMPHRIES
Journal:  JAMA       Date:  1961-04-01       Impact factor: 56.272

2.  St. Anthony's fire rekindled: gangrene due to therapeutic dose of ergotamine.

Authors:  E A CAMERON; E B FRENCH
Journal:  Br Med J       Date:  1960-07-02

3.  Ergot poisoning in acute hepatic necrosis.

Authors:  M J Whelton; A Allaway; A Stewart; L Kreel
Journal:  Gut       Date:  1968-06       Impact factor: 23.059

4.  Ergotism due to therapeutic doses of ergotamine tartrate.

Authors:  I Enge; E Sivertssen
Journal:  Am Heart J       Date:  1965-11       Impact factor: 4.749

5.  Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration.

Authors:  V Ala-Hurula; V V Myllylä; P Arvela; J Heikkilä; N Kärki; E Hokkanen
Journal:  Eur J Clin Pharmacol       Date:  1979-02-19       Impact factor: 2.953

  5 in total
  1 in total

1.  Bioavailability of dihydroergotamine in man.

Authors:  P J Little; G L Jennings; H Skews; A Bobik
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.